Skip to main content
. Author manuscript; available in PMC: 2018 Apr 30.
Published in final edited form as: Int J Cancer. 2016 Jan 28;138(10):2487–2498. doi: 10.1002/ijc.29989

Figure 8.

Figure 8

Combination treatment with GW788388 and IL-23 sustains increased Th17 cell levels in the spleen and lymph nodes of mice with premalignant oral lesions. Starting from Week 6 of 4NQO administration, when premalignant oral lesions were detectable on the tongue, mice were initiated on treatment with diluent, GW788388, IL-23 or both GW788388 and IL-23. After 2 months of these treatments, spleens and lymph nodes were collected and were surface immunostained for CD4 and stained intracellularly for IL-17. Shown are percentages of spleen cells and lymph node cells staining positive for CD4 plus IL-17. ** = p <0.01, *** = p <0.001.